(redirected from Qutenza)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to capsaicin

colorless pungent crystalline compound derived from capsicum

References in periodicals archive ?
Averitas Pharma, a recently acquired Grunenthal Group company, has acquired the United States commercialisation rights for Qutenza (capsaicin) eight% after the acquisition of the product by Grunenthal on the same day, it was reported yesterday.
Averitas Pharma will be enhancing the commercial distribution model for Qutenza towards a specialty pharmacy and hub services model that makes it easier for patients to access the product and support health care professionals in prescribing and applying it.
German science-focused pharmaceutical company Grunenthal revealed on Monday that it has acquired additional global commercial rights for the dermal pain patch Qutenza (8% capsaicin) from Acorda Therapeutics Inc (USA).
Qutenza: a capsaicin 8% patch for the management of postherpetic neuralgia.
Patients were excluded (n = 48) if they were found not to suffer from PNP, a Qutenza patch was previously used, the medical file was incomplete, and the follow-up was missing.
Target: Qutenza / additional global commercial rights
[8] European Medicines Agency, Human Medicines deailed information for Qutenza, Capsaicin, ema/index.jsp?curl=pages/medicines/human/medicines/000909/ human_med_001008.jsp&mid=WC0b01ac058001d124.
M2 EQUITYBITES-November 8, 2018-GrA1/4nenthal Acquires Global Rights for Dermal Pain Patch Qutenza
M2 PHARMA-December 14, 2016-Grunenthal to acquire Qutenza European commercialisation rights
13 December 2016 - German drugmaker GrA1/4nenthal Group has entered into a definitive agreement with Japanese drugmaker Astellas Pharma Inc's Astellas Pharma Europe Ltd subsidiary for the exclusive rights to the dermal patch Qutenza (capsaicin 8%) in Europe, Middle East and Africa, the company said.
M2 EQUITYBITES-November 5, 2018-GrA1/4nenthal announces acquisition of additional global commercial rights for dermal pain patch Qutenza from Acorda Therapeutics
Biotechnology company Acorda Therapeutics Inc (Nasdaq:ACOR) revealed on Tuesday that it has completed its acquisition of two neuropathic pain management assets, Qutenza and NP-1998, from NeurogesX Inc (OTC Markets:NGSX).